O blogueiro do WSJ destacou a condenação a morte do ex-diretor do equivalente à ANVISA chinesa. Denuncio aqui a sentença de morte e gostaria de conhecer o nome das oito companhias que participaram da "mutreta".
Death Sentence for China’s Former Top Drug Regulator Posted by Jacob Goldstein
Zheng Xiaoyu, the first chief of China’s State Food and Drug Administration, was sentenced to death today for taking $850,000 in bribes from eight unnamed drug companies, WSJ.com reports.The sentence comes as China struggles with a series of domestic and international incidents arising from food and medicines — ranging from pet chow to toothpaste to antibiotics. Zheng (pictured, left) ran China’s FDA from its founding in 1998 until 2005, the New York Times reports He was detained in February along with two other top regulators. Officials are now reviewing over 170,000 licenses issued by the agency over the past decade, according to the Times. The death sentence, handed down by Beijing Municipal No. 1 Intermediate People’s Court, said that Zheng’s acts “endangered public life and health and had a very negative social impact,” according to China’s Xinhua news service
Zheng Xiaoyu, the first chief of China’s State Food and Drug Administration, was sentenced to death today for taking $850,000 in bribes from eight unnamed drug companies, WSJ.com reports.The sentence comes as China struggles with a series of domestic and international incidents arising from food and medicines — ranging from pet chow to toothpaste to antibiotics. Zheng (pictured, left) ran China’s FDA from its founding in 1998 until 2005, the New York Times reports He was detained in February along with two other top regulators. Officials are now reviewing over 170,000 licenses issued by the agency over the past decade, according to the Times. The death sentence, handed down by Beijing Municipal No. 1 Intermediate People’s Court, said that Zheng’s acts “endangered public life and health and had a very negative social impact,” according to China’s Xinhua news service
Nenhum comentário:
Postar um comentário